Conestoga Capital Advisors LLC Has $129.34 Million Stake in Repligen Corporation $RGEN

Conestoga Capital Advisors LLC lifted its holdings in Repligen Corporation (NASDAQ:RGEN) by 3.8% during the 1st quarter, Holdings Channel reports. The fund owned 1,097,783 shares of the biotechnology company’s stock after acquiring an additional 39,808 shares during the quarter. Repligen makes up approximately 2.6% of Conestoga Capital Advisors LLC’s portfolio, making the stock its 16th biggest position. Conestoga Capital Advisors LLC’s holdings in Repligen were worth $129,341,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of RGEN. Measured Wealth Private Client Group LLC acquired a new stake in Repligen during the 3rd quarter valued at $29,000. Bayforest Capital Ltd acquired a new position in Repligen in the fourth quarter worth $32,000. Rachor Investment Advisory Services LLC acquired a new position in Repligen in the fourth quarter worth $33,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen during the fourth quarter worth $36,000. Finally, Farther Finance Advisors LLC grew its holdings in shares of Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.60% of the stock is currently owned by corporate insiders.

Repligen Stock Up 1.9%

Repligen stock opened at $138.99 on Thursday. The firm has a market capitalization of $7.84 billion, a price-to-earnings ratio of 154.44, a PEG ratio of 2.63 and a beta of 1.06. The company’s 50 day simple moving average is $123.28 and its 200 day simple moving average is $134.85. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. The company had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period last year, the business posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts anticipate that Repligen Corporation will post 1.99 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RGEN. HC Wainwright lifted their price target on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd. JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Rothschild & Co Redburn set a $160.00 target price on shares of Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Wolfe Research began coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price on the stock. Finally, Roth Mkm started coverage on shares of Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.